EZH2 and fragile X syndrome: We therefore derived efficacious ASOs targeting EZH2 and demonstrate that they reactivate <i>FMR1</i> expression and correct molecular and electrophysiological abnormalities in cultured FXS neurons, and reactivate <i>FMR1</i> expression in human FXS NPCs engrafted within the brains of mice.